Novo's Obesity Shot Shortfall Shows Danger of Promising Too Much [Yahoo! Finance Canada]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance Canada
Most Read from Bloomberg The Danish drugmaker repeatedly told investors that CagriSema, expected to be launched in 2026, would help people lose 25% or more of their body weight. Instead, patients on the experimental drug lost 20.4% in a study, putting the treatment on par with what arch rival Eli Lilly & Co. already has on the market in Zepbound. Reaction from the markets was swift and brutal. Novo shares fell as much as 27% in Copenhagen on Friday, at one point wiping out $120 billion from its market value. While Novo is trying to claw back some lost ground by promising to start another trial in the first half of next year to better calibrate doses, the damage seems to have been done. The company has been counting on CagriSema to help it ward off a growing roster of competitors, led by Lilly, in a weight-loss market that's predicted to grow to $130 billion by 2030. The disappointing study results now put pressure on the company to find ways to beef up its pipeline of experimen
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- US Approves First Drug Treatment For Sleep Apnea [Barron's]Barrons
- FDA approves weight-loss drug Zepbound for obstructive sleep apnea [CNN]CNN
- Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints [Yahoo! Finance]Yahoo! Finance
- FDA approves weight loss drug Zepbound for sleep apnea [MSNBC.com]MSNBC.com
- FDA Approves First Medication for Obstructive Sleep Apnea [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/24 - Miss
LLY
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- LLY's page on the SEC website